Ignite Creation Date:
2025-12-25 @ 1:08 AM
Ignite Modification Date:
2026-01-01 @ 11:39 PM
Study NCT ID:
NCT02609893
Status:
COMPLETED
Last Update Posted:
2020-10-22
First Post:
2015-10-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D019698', 'term': 'Hepatitis C, Chronic'}], 'ancestors': [{'id': 'D006526', 'term': 'Hepatitis C'}, {'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D006525', 'term': 'Hepatitis, Viral, Human'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018178', 'term': 'Flaviviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D006521', 'term': 'Hepatitis, Chronic'}, {'id': 'D006505', 'term': 'Hepatitis'}, {'id': 'D008107', 'term': 'Liver Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 31}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-10', 'completionDateStruct': {'date': '2019-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-10-20', 'studyFirstSubmitDate': '2015-10-05', 'studyFirstSubmitQcDate': '2015-11-17', 'lastUpdatePostDateStruct': {'date': '2020-10-22', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2015-11-20', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2018-04', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of people who inject drugs (PWIDs) with HCV who were recruited and retained', 'timeFrame': '44 weeks', 'description': 'To determine the feasibility of treating active PWIDs for HCV with LDV-SOF by mDOT versus unobserved dosing based on proportion eligible and enrolled among those screened and completion rates overall and by arm.'}, {'measure': 'Medication adherence to study drug', 'timeFrame': '44 weeks', 'description': 'To evaluate the acceptability of mDOT versus unobserved dosing, the percent of treatment medication adherence to LDV-SOF, as measured by the percent of doses taken overall (observed and unobserved), will be assessed using DOT doses and weekend Wise Pill data for the mDOT arm, and WisePill data for the unobserved dosing arm.'}, {'measure': 'Challenges of medication adherence', 'timeFrame': '44 weeks', 'description': 'To assess through in-depth, semi-structured qualitative interviews, the challenges with time intensity required for mDOT versus unobserved dosing for PWIDs treated with LDV-SOF.'}], 'secondaryOutcomes': [{'measure': 'SVR (end-of-treatment response)', 'timeFrame': '12 weeks', 'description': 'We will compare the proportion of participants with undetectable HCV RNA at week 8 and post-treatment week 12 between arms.'}, {'measure': 'SOF/metabolite levels', 'timeFrame': '8 weeks', 'description': 'SOF/metabolite-positivity rates will be calculated by week in both arms.'}, {'measure': 'HCV relapse and reinfection', 'timeFrame': '36 weeks', 'description': 'Among participants who achieve SVR, we will determine the proportion who experience HCV relapse and reinfection at post-treatment week 36, overall and by arm.'}, {'measure': 'Social and injector networks of participants', 'timeFrame': '44 weeks', 'description': 'We will characterize injector network sizes at baseline and follow-up through ACASI surveys.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['HCV'], 'conditions': ['Chronic Hepatitis C']}, 'referencesModule': {'references': [{'pmid': '31158245', 'type': 'DERIVED', 'citation': 'Coffin PO, Santos GM, Behar E, Hern J, Walker J, Matheson T, Kinnard EN, Silvis J, Vittinghoff E, Fox R, Page K. Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs. PLoS One. 2019 Jun 3;14(6):e0217471. doi: 10.1371/journal.pone.0217471. eCollection 2019.'}]}, 'descriptionModule': {'briefSummary': 'This project is a randomized trial of two strategies to treat persons with genotype 1 HCV who currently inject drugs (PWIDs) with a once daily regime of ledipasvir-sofosbuvir (LDV-SOF) for 8 weeks. The study will enroll 30 participants and will assess the feasibility and acceptability of treating active PWIDs for HCV with LDV-SOF by modified directly observed therapy (mDOT) versus unobserved dosing, with motivational interviewing based adherence support; and assess through in-depth, semi-structured qualitative interviews, the challenges with time intensity required for mDOT and unobserved dosing interventions, and identify key factors affecting treatment adherence.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. ≥18 years of age;\n2. 2 consecutive positive HCV RNA tests at least 6 months after estimated date of infection;\n3. HCV genotype 1;\n4. HCV RNA \\<6 million copies by Roche TaqMan Assay\n5. No evidence of hepatic cirrhosis (as determined by two indices: Fib4\\<3.25-an accurate test for detecting cirrhosis based on age, AST, ALT and platelets \\[sensitivity/specificity 76-100/82-91%\\], confirmed by the fibrosis-cirrhosis index (FCI)\\<1.25 based on ALT, bilirubin, albumin and platelets \\[sensitivity/specificity 86/100%\\]);\n6. Drug injection in past 30 days by self-report and physical exam evidence of injection drug use (e.g. track marks),\n7. injected with others in past 12 months by self-report;\n8. Lab values within acceptable range (platelets\\>50,000, creatinine clearance by Cockroft-Gault\\>30mL/min, hemoglobin \\>10g/dL, INR\\<1.5 x upper limit of normal (ULN) unless stable on anticoagulant regimen or known hemophilia, AST/ALT\\<10 x ULN);\n9. Able to speak English;\n10. No plans to leave San Francisco area for at least 9 months and either lives or works in San Francisco, or travels to San Francisco at least weekly;\n11. for women of childbearing age, pregnancy test negative, not actively nursing, and agree to use birth control during treatment (although LDV-SOF has a "B" rating, consistent with no known evidence of harm, treatment is not urgent for these patients so we will err on the side of caution).\n\nExclusion Criteria:\n\n1. HIV+ by rapid test or pooled viral load;\n2. HBV surface antigen +;\n3. Non-definitive HCV genotype results;\n4. Previously received treatment for HCV (interferon, ribavirin, or DAA);\n5. Taking medications that affect pharmacokinetics of LDV-SOF (proton-pump inhibitors, anticonvulsants \\[phenobarbital, phenytoin, carbamazepine, oxcarbazepine\\], rifamycins, rosuvastatin, herbs \\[St. John\'s wort, silymarin, echinacea\\]);\n6. History of any of the following:\n\n 1. Current gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug\n 2. History of hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage)\n 3. History of solid organ or bone marrow transplantation.\n 4. Current treatment for cancer\n7. Chronic liver disease for non HCV reason, except iron overload (e.g., Wilson\'s disease, alfa 1 antitrypsin deficiency, cholangitis);\n8. Use of any prohibited concomitant medications as described in Section 5.2 within 21 days of the Day 1 visit; and\n9. Known hypersensitivity to LDV, SOF, the metabolites, or formulation excipients.\n10. No other conditions that preclude study involvement as determined by PI.'}, 'identificationModule': {'nctId': 'NCT02609893', 'acronym': 'BYE-C', 'briefTitle': 'Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs', 'organization': {'class': 'OTHER_GOV', 'fullName': 'San Francisco Department of Public Health'}, 'officialTitle': 'Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs', 'orgStudyIdInfo': {'id': '1R34DA039333', 'link': 'https://reporter.nih.gov/quickSearch/1R34DA039333', 'type': 'NIH'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Modified Directly Observed Therapy', 'description': 'Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) observed daily dosing (modified for non-observed Saturday and Sunday dosing) for 8 weeks', 'interventionNames': ['Other: modified directly observed therapy (mDOT)', 'Other: Motivational Interviewing-based counseling']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Unobserved Dosing', 'description': 'Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) provided weekly (7 tablets) for unobserved daily dosing for 8 weeks', 'interventionNames': ['Other: unobserved dosing', 'Other: Motivational Interviewing-based counseling']}], 'interventions': [{'name': 'modified directly observed therapy (mDOT)', 'type': 'OTHER', 'armGroupLabels': ['Modified Directly Observed Therapy']}, {'name': 'unobserved dosing', 'type': 'OTHER', 'armGroupLabels': ['Unobserved Dosing']}, {'name': 'Motivational Interviewing-based counseling', 'type': 'OTHER', 'description': 'Motivational Interviewing-based risk reduction and medication adherence counseling', 'armGroupLabels': ['Modified Directly Observed Therapy', 'Unobserved Dosing']}]}, 'contactsLocationsModule': {'locations': [{'zip': '94102', 'city': 'San Francisco', 'state': 'California', 'country': 'United States', 'facility': 'Substance Use Research Unit', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}], 'overallOfficials': [{'name': 'Phillip O Coffin, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'San Francisco Department of Public Health'}, {'name': 'Emily Behar, MS', 'role': 'STUDY_DIRECTOR', 'affiliation': 'San Francisco Department of Public Health'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Phillip Coffin, MD, MIA', 'class': 'OTHER_GOV'}, 'collaborators': [{'name': 'National Institute on Drug Abuse (NIDA)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Director, Substance Use Research Unit', 'investigatorFullName': 'Phillip Coffin, MD, MIA', 'investigatorAffiliation': 'San Francisco Department of Public Health'}}}}